High Ly6D mRNA expression in breast cancer was significantly correlated with decreased three-year metastasis free survival (metastasis, n=79 vs metastasis free, n=85), decreased five-year metastasis free survival (metastasis, n=172 vs metastasis free, n=14), decreased three-year survival (dead, n=73 vs alive, n=496) decreased five-year survival (dead, n=42 vs alive, n=60) in Minn [48], Bild [51], Kao [52], Bos [71], and Essermann [56] studies. This evidence concerns the gene LY6D and breast cancer.